- This event has passed.
From Scientist to Founder: David Llewellyn On DJS Antibodies’ $255M Exit
November 16 @ 12:30 pm - 2:00 pm
In recent years, the field of biotechnology has witnessed a remarkable surge in scientific and technological breakthroughs, driving progress across healthcare, agriculture, and environmental sustainability. Within this dynamic landscape, innovative biotech startups have emerged as pivotal players, catalyzing transformative developments.
DJS Antibodies is one such trailblazing biotechnology company, dedicated to forging the future of antibody therapeutics. Spearheading this endeavor is David Llewellyn, the company’s managing director and co-founder, whose mission is to engineer antibodies combating chronic inflammatory diseases.
The culmination of their efforts reached a significant milestone in October 2022 when DJS Antibodies was acquired by AbbVie for a staggering $255 million. This strategic partnership promises to bolster research capabilities and fortify AbbVie’s immunology portfolio.
On November 16, David will detail his journey with DJS Antibodies in a global keynote for Founders Network. During the event, he’ll share how his passion for exploring medical advancements led him to establish a cutting-edge biotech startup worth millions.
David will also cover:
- Creative strategies for funding a business in the idea phase
- Practical tips for how to accomplish more with less capital
- Insights into how to close an M&A deal
- How to identify who will help and hinder you during your startup journey
- November 16
12:30 pm - 2:00 pm